A multidisciplinary working group of clinical specialists in Saudi Arabia has developed a comprehensive set of consensus statements to standardize prophylaxis strategies against SARS-CoV-2 infection among adult patients diagnosed with hematological malignancies. Published in Cancer Reports, the consensus addresses an urgent clinical priority stemming from the profound vulnerability observed in immunocompromised oncology populations throughout both the acute pandemic and ongoing endemic phases. Individuals suffering from malignant hematological disorders face disproportionately elevated hazards of severe coronavirus illness, intensive care unit admission, mechanical ventilation, protracted viral shedding, and death compared with the broader population. This amplified susceptibility arises directly from underlying neoplastic processes affecting the immune system as well as the aggressive immunosuppressive regimens required to treat them, including systemic chemotherapy, ionizing radiation, hematopoietic stem cell transplantation, and targeted immunomodulatory agents. Even as community-level mortality rates have declined in the wider population, clinical evidence consistently demonstrates that patients with hematological cancers continue to experience high rates of adverse outcomes, requiring specialized, evidence-based preventive measures that integrate behavioral safeguards, active immunization, and passive antibody administration.
The consensus initiative responds directly to a substantial epidemiological burden of hematological malignancies documented across the Kingdom of Saudi Arabia over recent decades. Prior epidemiological assessments in the country have established that leukemia represents the most common malignancy diagnosed among Saudi males, constituting approximately eight percent of all male cancer cases recorded in 2020. Simultaneously, non-Hodgkin lymphoma and Hodgkin lymphoma have advanced to become the third and sixth most frequently diagnosed cancers among Saudi males, respectively, with lymphoma diagnoses collectively representing approximately 12.4 percent of all newly detected cancer cases nationwide in 2020. Historical surveillance registry data have further recorded an alarming increase of nearly one hundred percent in the overall incidence of Hodgkin lymphoma within the Kingdom between 2001 and 2020. Given this substantial domestic disease volume and the distinct clinical trajectories observed in immunocompromised cancer patients encountering viral pathogens, the national expert panel determined that formulating locally adapted, structured prophylaxis guidelines was vital to safeguard vulnerable cohorts and streamline clinical decision-making across regional healthcare centers.
To formulate these clinical recommendations, the Working Group on COVID-19 Management in Hematological Malignancies convened a nine-member expert panel representing academic and clinical healthcare institutions located across Riyadh, Jeddah, Makkah, and Jazan. Panelist selection was executed through non-probability purposive sampling based upon stringent eligibility criteria, requiring demonstrated clinical specialization in hematology, hematopoietic stem cell transplantation, medical oncology, or adult transplant infectious diseases, accompanied by an active research or publication record in hematological disorders or viral management. The final voting panel was composed of five specialists in hematology or hematopoietic stem cell transplantation, two medical oncologists, and two infectious disease or transplant infectious disease physicians. Formal methodological convergence was achieved through a modified three-step Delphi technique, which integrated an initial electronic survey, an intermediate moderated virtual advisory board meeting to resolve contentious areas, and a concluding electronic voting iteration. All participating experts submitted formal declarations of interest prior to questionnaire administration, and individual votes were cast anonymously via a secure online platform to prevent the disproportionate influence of dominant panel members during early deliberative stages.
The development of specific statements began with an exhaustive review of published biomedical literature across major electronic research databases, including PubMed, Embase, and the Cochrane Library, supplemented by targeted manual reviews of relevant international oncology guidelines and reference lists. Literature searches utilized comprehensive keyword combinations encompassing coronavirus disease, specific hematological neoplasms, vaccination protocols, passive immunization, and immunosuppression, restricting eligible source material to English-language publications without publication date restrictions while prioritizing high-quality evidence. From this retrieved evidence base, the investigators formulated an initial questionnaire consisting of 27 draft statements structured into five defined domains: general preventive strategies, general vaccination recommendations, special vaccination recommendations, pharmacological prophylaxis, and unmet medical needs. In the initial electronic Delphi round, panel consensus was predefined as achieving an agreement proportion of at least 80 percent among all submitted votes, including recorded abstentions in the denominator. Eleven statements fulfilled this consensus threshold during the initial round, while the remaining draft statements were carried forward into the moderated virtual advisory board session, where four statements were eliminated, one new statement was added, and existing statements underwent rigorous refinement regarding terminology, feasibility, and evidence alignment.
Following subsequent electronic recirculation of the revised statements to all nine expert panelists, the working group established a final framework comprising 24 consensus statements. Within this final set, 23 statements achieved unanimous 100 percent agreement among the voting experts, while one pharmacological statement attained 88.9 percent agreement based on eight affirmative votes and one recorded abstention. Four final statements established the essential role of non-pharmaceutical interventions alongside active immunization for patient contacts. The panel concluded that non-pharmaceutical protective measures, including social distancing, protective mask-wearing, and meticulous hand hygiene, remain strongly indicated for individuals with hematological malignancies, especially during documented periods of heightened community viral transmission. To create a protective cocoon effect, the panel strongly advised that all household cohabitants and primary caregivers receive updated COVID-19 vaccines to interrupt household transmission pathways. Similarly, strict adherence to non-pharmaceutical protocols and up-to-date vaccination was deemed essential for all healthcare personnel and clinical unit staff working in close physical proximity with immunocompromised hematology patients.
Within the preventive domain, the expert panel specifically addressed the contentious clinical application of granulocyte-colony stimulating factors in neutropenic cancer patients who develop concurrent SARS-CoV-2 infection. Although granulocyte-colony stimulating factors are routinely prescribed in oncology practice to shorten the duration and diminish the severity of chemotherapy-induced neutropenia, indirect clinical evidence and narrative evaluations suggest that their administration during active viral infection may trigger exaggerated inflammatory responses and inflammatory cytokine release, potentially exacerbating coronavirus-induced pulmonary injury and precipitating acute respiratory distress syndrome. Consequently, Statement 4 mandates that attending physicians carefully weigh the potential clinical risks against therapeutic benefits before administering these growth factors to neutropenic cancer patients with active infection, ensuring management decisions are individualized according to the depth of neutropenia, baseline clinical stability, and competing thrombotic or infectious hazards.
Active immunization using updated vaccine formulations was designated by the panel as the frontline prophylactic strategy to prevent SARS-CoV-2 infection and mitigate severe complications across all adult hematological cancer cohorts, regardless of prior infection history, transplant status, or expected serological response rates. The consensus emphasizes that vaccine selection should align with prevailing national recommendations and institutional supply, ensuring every patient receives at least one dose of an updated formulation. For patients aged 65 years and older, who carry an elevated risk of breakthrough illness, the panel recommended administering an additional updated vaccine dose at least two months after the prior administration. Addressing clinical concerns regarding treatment timing, the panel affirmed that contemporary observational safety cohort studies demonstrate no heightened safety risks or treatment-related toxicities linked to vaccination in non-transplant cohorts. Therefore, routine cancer therapies must never be delayed to accommodate vaccination schedules. Non-transplant patients who receive vaccination before or during antineoplastic therapy should undergo clinical reassessment three to six months following treatment cessation and be offered revaccination, with ongoing booster reassessments repeated every six months to sustain neutralizing defenses against newly circulating viral variants.
The expert panel formulated specialized vaccination schedules for patients undergoing scheduled antineoplastic procedures, chemotherapy, or immunosuppressive therapy, advising that an updated vaccine dose be administered at least two weeks before initiating interventions whenever clinically feasible. Following immunosuppressive interventions, patients should receive a second vaccine dose within the initial three months, followed by an additional booster dose two months thereafter. For individuals receiving targeted immunotherapies that deplete humoral immunity, such as anti-CD20 monoclonal antibodies or bispecific monoclonal antibodies, vaccination remains strongly indicated despite recognized reductions in vaccine-induced antibody production. Furthermore, because conditioning regimens and cellular ablative therapies erase preexisting immune memory, patients undergoing allogeneic or autologous hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy should initiate full vaccination six months post-treatment, with consideration for earlier administration during periods of severe community transmission, followed by routine semiannual revaccination reassessments. In the allogeneic transplant setting, immunizing donors two weeks before cell harvest was additionally endorsed to potentially transfer protective donor immunity to recipients.
In the pharmacological domain, the working group emphasized systematic risk stratification to identify immunocompromised individuals who exhibit inadequate serological responses to active immunization and require pre-exposure passive prophylaxis. High-risk groups prioritized for pre-exposure monoclonal antibody prophylaxis include unvaccinated individuals, patients demonstrating inadequate antibody titers following complete vaccination, and patients undergoing therapy for lymphoproliferative disorders, acute leukemia, or multiple myeloma, particularly those exposed to anti-CD20 antibodies or B-cell maturation antigen-targeted bispecific antibodies within the preceding six to 12 months. Additional high-priority groups encompass patients undergoing induction chemotherapy for acute leukemia, those with profound hypogammaglobulinemia below 4 grams per liter, deep lymphopenia below 500 cells per microliter, recipients of recent stem cell transplants, individuals maintained on high-dose corticosteroids for two or more weeks, and patients exhibiting persistent B-cell aplasia after chimeric antigen receptor T-cell administration.
Crucially, the consensus stipulates that pre-exposure prophylaxis utilizing long-acting monoclonal antibodies must remain contingent upon contemporary laboratory surveillance demonstrating that the specific pharmaceutical agent retains neutralizing activity against prevailing circulating subvariants within Saudi Arabia, alongside official domestic regulatory authorization and product availability. The panel underscored that historical trial successes, such as the 77 percent relative risk reduction achieved by tixagevimab and cilgavimab in the Phase 3 PROVENT trial, represent historical proof of concept that cannot be generalized to novel viral subvariants that have evolved resistance. The working group reviewed emerging pipeline agents including sipavibart, which met its primary prevention endpoint in the Phase 3 SUPERNOVA trial, VYD222, and REGN17092. When indicated, monoclonal antibodies should be initiated promptly upon risk identification, even during scheduled cancer therapy, but must be spaced at least two weeks after active vaccine administration. Conversely, the panel explicitly advised against utilizing high-titer convalescent plasma or repurposed antiviral medications, such as remdesivir, nirmatrelvir-ritonavir, or molnupiravir, for pre- or post-exposure prophylaxis due to a lack of efficacy data in oncology cohorts.
The consensus concluded by identifying persistent unmet healthcare needs and acknowledging inherent methodological limitations in the available evidence base. The panel stressed the necessity of establishing a standardized, national multidisciplinary protocol across Saudi healthcare systems to harmonize preventive oncology care, expanding domestic genomic surveillance to track emergent viral variants, and securing rapid regulatory channels for next-generation therapeutic antibodies. The authors acknowledged that their recommendations were formulated by a nine-member panel selected through convenience sampling, which may constrain geographic and institutional representativeness across the Kingdom. Furthermore, because robust prospective randomized clinical trial data conducted directly among Saudi hematology patients remain scarce, many statements rely upon indirect evidence, observational registry studies, international guidelines, and multidisciplinary expert consensus rather than definitive local empirical trials. The investigators emphasized that evolving viral mutations necessitate regular clinical reevaluation of passive antibody guidelines to maintain therapeutic relevance across changing epidemiological landscapes.
Subject of Research: Consensus recommendations for SARS-CoV-2 prophylaxis in adult hematological malignancy patients in Saudi Arabia
Article Title: Prophylaxis Strategies for SARS‐CoV‐2 Infection in Adults With Hematological Malignancies in Saudi Arabia: Consensus Statements From the Working Group on COVID‐19 Management in Hematological Malignancies
Article References: Al‐Mansour, M., Alhejazi, A., Alsaggaf, M. A., Malhan, H. M., El Fakih, R., Dada, R., Alotaibi, G. S., Almaghrabi, R. S., & Alshamrani, M. (2026). Prophylaxis Strategies for SARS ‐ CoV ‐2 Infection in Adults With Hematological Malignancies in Saudi Arabia: Consensus Statements From the Working Group on COVID ‐19 Management in Hematological Malignancies. Cancer Reports, 9(10), Article e70730. https://doi.org/10.1002/cnr2.70730
Image Credits: AI Generated
DOI: 10.1002/cnr2.70730
Keywords: Hematological Malignancies, COVID-19 Prophylaxis, Delphi Consensus, Saudi Arabia, Monoclonal Antibodies, Vaccine Immunogenicity, Stem Cell Transplantation, Immunocompromised Patients, Prophylaxis, Strategies, SARS, Infection
News Source: Kristina Jarvis. (November 7, 2026). Saudi Expert Panel Establishes COVID-19 Prophylaxis Consensus for Hematological Malignancies. Scienmag.



